Earnings summaries and quarterly performance for Dare Bioscience.
Executive leadership at Dare Bioscience.
Board of directors at Dare Bioscience.
Research analysts who have asked questions during Dare Bioscience earnings calls.
DT
Douglas Tsao
H.C. Wainwright & Co.
3 questions for DARE
Also covers: ALKS, APLS, ARGX +19 more
Catherine Novack
JonesTrading Institutional Services LLC
2 questions for DARE
Also covers: ALDX, CAPR, CRNX +3 more
BK
Brian Kemp Dolliver
Brookline Capital Markets, LLC
1 question for DARE
Also covers: , BIOX, ICCM +6 more
Will Hidell
Brookline Capital Markets
1 question for DARE
Also covers: IMNN, LSTA, OTLK
Recent press releases and 8-K filings for DARE.
Daré Bioscience Regains Full Rights to Ovaprene from Bayer
DARE
New Projects/Investments
M&A
Guidance Update
- Daré Bioscience announced that all rights to Ovaprene®, its investigational hormone-free monthly intravaginal contraceptive, will be returned by Bayer HealthCare LLC, effective February 2026, due to Bayer's strategic prioritization.
- The return of rights provides Daré with full control of Ovaprene, a late-stage asset with an ongoing Phase 3 clinical study supported by non-dilutive grant funding.
- Positive interim data from the Phase 3 trial was announced in July 2025, demonstrating consistent safety and tolerability, and the study is progressing towards anticipated enrollment completion in 2026.
- Daré will no longer receive future license fees or milestone payments from Bayer, but a $1.0 million upfront non-refundable license fee will be recorded as license revenue upon termination. The company expects the termination to not materially impact the ongoing Phase 3 study.
Dec 1, 2025, 1:01 PM
DARE Bioscience Reports Q3 2025 Results and Anticipates Q4 Revenue from Product Launch
DARE
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- DARE Bioscience ended Q3 2025 with approximately $23 million in cash and cash equivalents and $3.8 million in working capital, having received $18.7 million in net proceeds from common stock sales and $7.3 million in grant payments during the quarter.
- The company is on track to launch Dare to Play Sildenafil Cream through a 503(b) outsourcing facility in December 2025, with availability in all 50 states by early 2026, and expects initial revenue recognition in Q4 2025.
- DARE plans to expand its commercial portfolio with Dare to Restore vaginal probiotic products in Q1 2026 and Dare to Reclaim (estradiol and progesterone intravaginal ring) via 503(b) in early 2027, both expected to generate meaningful revenue.
- The clinical pipeline continues to advance with non-dilutive funding, including Oviprene (Phase III, enrollment completion anticipated in 2026, with potential payments from Bayer of $20 million and up to $310 million in milestones) and grant-funded programs like DARE HPV, DARE LARK 1, and DARE NHC.
Nov 13, 2025, 9:30 PM
Dare Bioscience Reports Q3 2025 Financial Results and Product Updates
DARE
Earnings
Product Launch
New Projects/Investments
- Dare Bioscience reported a net loss of $(3.56) million and a loss per common share of $(0.28) for the third quarter ended September 30, 2025.
- As of September 30, 2025, the company held approximately $23.1 million in cash and cash equivalents and $3.8 million in working capital.
- DARE to PLAY™ Sildenafil Cream is on track for initial prescription fulfillment in December 2025, expected to generate near-term product revenue.
- The Ovaprene® Phase 3 study received a positive interim DSMB recommendation in July 2025, supporting continued enrollment.
- General and Administrative expenses increased to $2.5 million in Q3 2025, while Research and Development expenses decreased by 56% to $1.2 million in Q3 2025, primarily due to increased contra R&D expenses from non-dilutive funding.
Nov 13, 2025, 9:01 PM
Dare Bioscience Reports Q3 2025 Financial Results and Anticipates Near-Term Product Revenue
DARE
Earnings
Product Launch
New Projects/Investments
- Dare Bioscience reported $23.1 million in cash and cash equivalents and $3.8 million in working capital as of September 30, 2025.
- DARE to PLAY™ Sildenafil Cream is on track for initial prescription fulfillment in December, expected to generate near-term revenue via the 503B pathway.
- The Ovaprene® Phase 3 study received a positive interim DSMB recommendation in July 2025, supporting continued enrollment.
- The company anticipates four commercially available solutions for women over the next two years, including DARE to RESTORE™ Vaginal Probiotics in Q1 2026 and DARE to RECLAIM™ Monthly Hormone Therapy in early 2027.
Nov 13, 2025, 9:01 PM
Daré Bioscience Receives Grant Funding for Drug Delivery System
DARE
New Projects/Investments
- Daré Bioscience received a $4.0 million non-dilutive funding installment, bringing the total grant funding received to approximately $41.8 million out of an up to $49 million committed grant.
- This funding supports the development of DARE-LARC1, a preclinical-stage long-acting reversible contraceptive (LARC) that utilizes the company's intelligent drug delivery system (DARE-IDDS) platform.
- The DARE-IDDS platform has broader market potential beyond reproductive health, including applications in obesity, diabetes, and other chronic conditions.
- The company is eligible for up to an additional $7.1 million in non-dilutive funding for the DARE-LARC1 program, contingent on achieving specified milestones.
Oct 6, 2025, 12:00 PM
Quarterly earnings call transcripts for Dare Bioscience.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more